Patents by Inventor Andrew D. Hamilton
Andrew D. Hamilton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120035184Abstract: Methods of inducing tumor regression, inhibiting tumor growth, and inducing apoptosis with selective peptidomimetic inhibitors of geranylgeranyltransferase I (GGTase I), are provided. In one aspect, GGTI-2418 and its methylester GGTI-2417, increase levels of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 and induce breast tumor regression in vivo. In another aspect, GGTI-2417 inhibits the Cdk2-mediated phosphorylation of p27Kip1 at Thr187 and accumulates p27Kip1 in the nucleus.Type: ApplicationFiled: July 29, 2011Publication date: February 9, 2012Applicants: Yale University, H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Said M. Sebti, Andrew D. Hamilton
-
Publication number: 20110223661Abstract: Disclosed herein are compounds derived from a chemical structure according to the formula (I) wherein X comprises oxygen or sulfur, R1 comprises a phenyl or naphthyl group, R2 comprises an amide group and R3 comprises a phosphate group. The disclosed compounds demonstrate inhibitory activity against STAT3, a protein found in certain tumor tissues and which promotes cellular overproliferation and resistance to apoptosis. The invention includes compositions containing the disclosed compounds, as well as methods of treatment therewith.Type: ApplicationFiled: September 17, 2009Publication date: September 15, 2011Applicant: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION,Inventors: James Turkson, Andrew D. Hamilton
-
Publication number: 20110124602Abstract: A small-molecule Stat3 dimerization inhibitor, S3I-M2001, is described and the dynamics of intracellular processing of activated Stat3 within the context of the biochemical and biological effects of the Stat3 chemical probe inhibitor are elucidated. S3I-M2001 is a newly-identified oxazole-based peptidomimetic of the Stat3 Src Homology (SH) 2 domain-binding phosphotyrosine peptide that selectively disrupts active Stat3:Stat3 dimers. Stat3-dependent malignant transformation, survival, and migration and invasion of mouse and human cancer cells harboring persistently-activated Stat3 were inhibited by S3I-M2001. S3I-M2001 inhibited Stat3-dependent transcriptional regulation of tumor survival genes, such as Bcl-xL. The disclosed compound is useful as a new potential treatment for certain cancers.Type: ApplicationFiled: December 5, 2007Publication date: May 26, 2011Inventors: James Turkson, Said Sebti, Richard Jove, Andrew D. Hamilton
-
Patent number: 7842671Abstract: The subject invention concerns compositions and methods for blocking cancer cell growth or proliferation and/or inducing cancer cell death. Compositions of the present invention are peptidomimetics that inhibit STAT function. Peptidomimetics of the invention include compounds of the formula RY*L (where Y* represents phosphotyrosine), with the R group at the Y-1 position. Peptidomimetics of the invention disrupt Stat3 activation and function. Peptidomimetics of the invention significantly inhibit tumor cell growth and induce tumor cell death.Type: GrantFiled: November 19, 2007Date of Patent: November 30, 2010Assignees: University of South Florida, Yale UniversityInventors: James Turkson, Richard Jove, Said M. Sebti, Andrew D. Hamilton
-
Publication number: 20100222352Abstract: The present invention relates to compounds according to the formula I: Where Ra is H or an optionally OH-substituted C1-C3 alkyl; R1 is OR1, an optionally substituted C4-12 carbocyclic group which may be saturated or unsaturated (including aromatic) or an optionally substituted heterocyclic group; R1 is an optionally substituted C1-C14 hydrocarbyl group or an optionally substituted heterocyclic group; R2, R3 and R4 are each independently H, an optionally substituted C1-C4 alkyl group (preferably CH3, CH2CH3 or CF3), halogen (preferably F, Cl, Br), OR, CN, NO2, a C1-C6 thioether, a C1-C6 thioester group, an optionally substituted CO2R group, an optionally substituted COR group or an optionally substituted OCOR group (preferably R4 is H); R is H or an optionally substituted C1-C6 alkyl group; RHET is an optionally substituted heterocyclic group; and pharmaceutically acceptable salts, solvates or polymorphs thereof.Type: ApplicationFiled: September 25, 2006Publication date: September 2, 2010Applicant: YALE UNIVERSITYInventors: William L. Jorgensen, Juliana Ruiz-Caro, Andrew D. Hamilton
-
Publication number: 20100210516Abstract: Growth factor binding molecules having a plurality of peptide loops attached to a non-peptide organic scaffold, preferably having pseudo-six amino acid peptide loops with four amino acid sidechains. The growth factor binding molecules specifically bind various growth factors and are suitable for treating a subject having tumors or restinosis. In one embodiment a platelet-derived growth factor binding molecule is disclosed that is used to inhibit tumor growth and angiogenesis in solid tumors.Type: ApplicationFiled: November 19, 2009Publication date: August 19, 2010Applicants: University of South Florida, Yale UniversityInventors: Said Sebti, Andrew D. Hamilton
-
Patent number: 7763620Abstract: The present invention relates to piperazinone compounds, pharmaceutical compositions containing those compounds and methods of treating tumors and cancer, among other disease states and conditions in mammalian patients, especially including humans.Type: GrantFiled: August 23, 2002Date of Patent: July 27, 2010Assignees: Yale University, University of South FloridaInventors: Andrew D. Hamilton, Said Sebti, Hairuo Peng
-
Patent number: 7718700Abstract: Growth factor binding compounds having a plurality of acyclic isophthalic acid groups attached to a non-peptide organic scaffold and pharmaceutical compositions of the same are disclosed. Methods of administering and using the growth factor binding compounds or the growth factor binding compositions are also taught. These novel growth factor binding compounds are useful for treating angiogenesis, excessive cellular proliferation, tumor growth, and a combination thereof as well as inhibiting growth factor binding to cells and phosphorylation.Type: GrantFiled: December 18, 2008Date of Patent: May 18, 2010Assignees: Yale University, University of South FloridaInventors: Said M. Sebti, Andrew D. Hamilton, Rishi Jain
-
Publication number: 20100009397Abstract: Disclosed herein is a species of peptide and non-peptide inhibitors of Akt, an oncogenic protein. Beginning with a residue of Akt target substrate GSK-3, the functional domains of the GSK-3 residue were characterized. Functionally homologous non-peptide groups were substituted for the amino acids of the GSK-3 creating a hybrid peptide-non-peptide and non-peptide compounds capable of binding to Akt. The non-peptide compounds show increased stability and rigidity compared to peptide counterparts and are less susceptible to degradation. The bound non-peptide compounds exhibit an inhibitory effect on Akt, similar to peptide-based Akt inhibitors.Type: ApplicationFiled: June 8, 2009Publication date: January 14, 2010Applicants: UNIVERSITY OF SOUTH FLORIDA, YALE UNIVERSITYInventors: Said M. Sebti, Jin Q. Cheng, Andrew D. Hamilton, Katherine Kayser-Bricker
-
Publication number: 20090318684Abstract: The subject invention concerns compositions and methods for blocking cancer cell growth or proliferation and/or inducing cancer cell death. Compositions of the present invention are compounds that inhibit Rho-protein associated kinase function. Compounds of the invention include piperazinyl pyridines, piperazinylmethyl pyridines, piperazinyl ureas and carbamates, piperazinyl pyridines and quinoilines (including isoquinliones) as well as piperazinyl (including piperazinylmethyl) pyridines and quinolines (including isoquinolines). Compounds of the invention disrupt Rho-kinase activation and function and significantly inhibit tumor cell growth and induce tumor cell death.Type: ApplicationFiled: June 22, 2009Publication date: December 24, 2009Applicants: UNIVERSITY OF SOUTH FLORIDA, YALE UNIVERSITYInventors: Said M. Sebti, Andrew D. Hamilton
-
Publication number: 20090318367Abstract: The subject invention concerns compositions and methods for blocking cancer cell growth or proliferation and/or inducing cancer cell death. Compositions of the present invention are peptidomimetics that inhibit STAT function. Peptidomimetics of the invention display selective inhibition of specific STAT isoform homo-dimerization. The peptidomimetic probes of STAT1 function, described herein, provide the means to preferentially inhibit STAT1 over STAT3 through the exploration of the C-terminus.Type: ApplicationFiled: June 8, 2009Publication date: December 24, 2009Applicants: University of South Florida, Yale UniversityInventors: Said M. Sebti, Andrew D. Hamilton, James Turkson, Richard Jove
-
Patent number: 7632805Abstract: Growth factor binding molecules having a plurality of peptide loops attached to a non-peptide organic scaffold, preferably having pseudo-six amino acid peptide loops with four amino acid sidechains. The growth factor binding molecules specifically bind various growth factors and are suitable for treating a subject having tumors or restinosis. In one embodiment a platelet-derived growth factor binding molecule is disclosed that is used to inhibit tumor growth and angiogenesis in solid tumors.Type: GrantFiled: September 14, 2005Date of Patent: December 15, 2009Assignees: University of South Florida, Yale UniversityInventors: Said Sebti, Andrew D. Hamilton
-
Publication number: 20090131487Abstract: Growth factor binding compounds having a plurality of acyclic isophthalic acid groups attached to a non-peptide organic scaffold and pharmaceutical compositions of the same are disclosed. Methods of administering and using the growth factor binding compounds or the growth factor binding compositions are also taught. These novel growth factor binding compounds are useful for treating angiogenesis, excessive cellular proliferation, tumor growth, and a combination thereof as well as inhibiting growth factor binding to cells and phosphorylation.Type: ApplicationFiled: December 18, 2008Publication date: May 21, 2009Inventors: Said M. Sebti, Andrew D. Hamilton, Rishi Jain
-
Patent number: 7482483Abstract: Growth factor binding compounds having a plurality of acyclic isophthalic acid groups attached to a non-peptide organic scaffold and pharmaceutical compositions of the same are disclosed. Methods of administering and using the growth factor binding compounds or the growth factor binding compositions are also taught. These novel growth factor binding compounds are useful for treating angiogenesis, excessive cellular proliferation, tumor growth, and a combination thereof as well as inhibiting growth factor binding to cells and phosphorylation.Type: GrantFiled: January 27, 2005Date of Patent: January 27, 2009Assignees: University of South Florida, Yale UniversityInventors: Said M. Sebti, Andrew D. Hamilton, Rishi Jain
-
Publication number: 20080221123Abstract: The present invention relates to piperazinone compounds, pharmaceutical compositions containing those compounds and methods of treating tumors and cancer, among other disease states and conditions in mammalian patients, especially including humans.Type: ApplicationFiled: August 23, 2002Publication date: September 11, 2008Inventors: Andrew D. Hamilton, Said Sebti, Hairuo Peng
-
Patent number: 7342095Abstract: The subject invention concerns compositions and methods for blocking cancer cell growth or proliferation and/or inducing cancer cell death. Compositions of the present invention are peptidomimetics that inhibit STAT function. Peptidomimetics of the invention include compounds of the formula RY*L (where Y* represents phosphotyrosine), with the R group at the Y-1 position. Peptidomimetics of the invention disrupt Stat3 activation and function. Peptidomimetics of the invention significantly inhibit tumor cell growth and induce tumor cell death.Type: GrantFiled: February 20, 2004Date of Patent: March 11, 2008Assignee: University of South FloridaInventors: James Turkson, Richard Jove, Said M. Sebti, Andrew D. Hamilton
-
Patent number: 7312246Abstract: The present invention relates to compounds and pharmaceutical compositions which are proteonaimetic and to methods for inhibiting the interaction of an alpha-helical protein with another protein or binding site. Methods for treating diseases or conditions which are modulated through interactions between alpha helical proteins and their binding sites are other aspects of the invention. In particular, the invention relates to treatment of viral infections using terphenyl derivatives.Type: GrantFiled: January 25, 2005Date of Patent: December 25, 2007Assignee: Yale UniversityInventors: Andrew D. Hamilton, Justin Ernst, Brendan Orner
-
Patent number: 7176287Abstract: The present invention provides a method for identifying a polypeptide that interacts with a known protein, which method uses fusion proteins with GFP fragments.Type: GrantFiled: March 15, 2004Date of Patent: February 13, 2007Assignee: Yale UniversityInventors: Andrew D. Hamilton, Indraneel Ghosh, Lynne Regan
-
Patent number: 7157419Abstract: Growth factor binding molecules having a plurality of peptide loops attached to a non-peptide organic scaffold, preferably having pseudo-six amino acid peptide loops with four amino acid sidechains. The growth factor binding molecules specifically bind various growth factors and are suitable for treating a subject having tumors or restinosis. In one embodiment a platelet-derived growth factor binding molecule is disclosed that is used to inhibit tumor growth and angiogenesis in solid tumors.Type: GrantFiled: March 21, 2001Date of Patent: January 2, 2007Assignee: University of South FloridaInventors: Said Sebti, Andrew D. Hamilton
-
Patent number: 6858600Abstract: The present invention relates to compounds and pharmaceutical compositions which are proteomimetic and to methods for inhibiting the interaction of an alpha-helical protein with another protein or binding site. Methods for treating diseases or conditions which are modulated through interactions between alpha helical proteins and their binding sites are other aspects of the invention.Type: GrantFiled: May 8, 2002Date of Patent: February 22, 2005Assignee: Yale UniversityInventors: Andrew D. Hamilton, Justin Ernst, Brendan P. Orner